Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy

被引：0
|
作者：
Corso, Alessandro [1 ]
Barbarano, Luciana [2 ]
Mangiacavalli, Silvia [1 ]
Montalbetti, Luigi
Brasca, Paola [2 ]
Zappasodi, Patrizia [1 ]
Carella, Angelo [3 ]
Spriano, Mauro [3 ]
Alessandrino, Emilio Paolo [1 ]
Cairoli, Roberto [2 ]
Petro, Daniela [2 ]
Varettoni, Marzia [1 ]
Bernasconi, Paolo [1 ]
Lazzarino, Mario [1 ]
Morra, Enrica [2 ]
机构：
[1] Univ Pavia, Fdn IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
[2] Osped Ca Granda, Div Hematol, Milan, Italy
[3] Osped San Martino Genova, Div Hematol, Genoa, Italy
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3595
引用
收藏
页码：1051A / 1052A
页数：2
相关论文
共 50 条
  • [41] ENHANCEMENT OF AMYLOIDOSIS BY HIGH-DOSE PREDNISOLONE THERAPY IN MULTIPLE-MYELOMA
    KANOH, T
    NAKAMURA, Y
    KAWAI, C
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 43 (01) : 83 - 83
  • [42] Hematologic recovery after high-dose therapy for multiple myeloma - Response
    Moreau, P
    Harousseau, JL
    BLOOD, 2002, 99 (11) : 4252 - 4252
  • [43] WHO BENEFITS FROM HIGH-DOSE THERAPY FOR MULTIPLE-MYELOMA
    ANDERSON, KC
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) : 1291 - 1296
  • [44] SEQUENTIAL HIGH-DOSE CORTICOSTEROID-THERAPY IN MULTIPLE-MYELOMA
    ARLET, P
    LAROCHE, M
    ADOUE, D
    SALLERIN, F
    VILAIN, C
    JUCHET, H
    LETALLEC, Y
    PRESSE MEDICALE, 1988, 17 (09): : 439 - 439
  • [45] Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma
    Hussein, M
    CLINICAL LYMPHOMA, 2003, 4 : S18 - S22
  • [46] Transplantation for multiple myeloma:: who, when, how often?: High-dose therapy in multiple myeloma
    Bladé, J
    BLOOD, 2003, 102 (10) : 3469 - 3470
  • [47] PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (VPD) AS INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATES TO AUTOLOGOUS TRANSPLANT
    Mangiacavalli, S.
    Montefusco, V.
    Pochintesta, L.
    Baldini, L.
    Ferretti, V.
    Farina, L.
    Cocito, F.
    Ravelli, E.
    La Targia, M. L.
    Cairoli, R.
    Corso, A.
    HAEMATOLOGICA, 2014, 99 : 363 - 364
  • [48] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [49] Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma
    Broijl, Annemiek
    Kersten, Marie Jose
    Alemayehu, Wendim Ghidey
    Levin, Mark-David
    de Weerdt, Okke
    Vellenga, Edo
    Meijer, Ellen
    Wittebol, Shulamiet
    Ghiraw-Visser, Rosita
    Stevens-Kroef, Marian
    Beverloo, Berna
    Bos, Gerard M. J.
    Wijermans, Pierre W.
    Lokhorst, Henk
    Sonneveld, Pieter
    BLOOD, 2014, 124 (21)
  • [50] Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma
    Cook, Joselle
    Johnson, Isla
    Higgins, Alexandra
    Sidana, Surbhi
    Warsame, Rahma
    Gonsalves, Wilson
    Gertz, Morie A.
    Buadi, Francis
    Lacy, Martha
    Kapoor, Prashant
    Dispenzieri, Angela
    Kourelis, Taxiarchis
    Dingli, David
    Fonder, Amie
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kyle, Robert
    Leung, Nelson
    Go, Ronald
    Rajkumar, Vincent S.
    Kumar, Shaji
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : 330 - 337
12345